The University of Chicago Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Mark W. Lingen and Nishant Agrawal.
Connection Strength

0.987
  1. Adjuncts for the evaluation of potentially malignant disorders in the oral cavity: Diagnostic test accuracy systematic review and meta-analysis-a report of the American Dental Association. J Am Dent Assoc. 2017 11; 148(11):797-813.e52.
    View in: PubMed
    Score: 0.153
  2. Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity: A report of the American Dental Association. J Am Dent Assoc. 2017 10; 148(10):712-727.e10.
    View in: PubMed
    Score: 0.152
  3. Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jul 01; 10(7):923-931.
    View in: PubMed
    Score: 0.061
  4. Acquired resistance to immunotherapy and chemoradiation in MYC amplified head and neck cancer. NPJ Precis Oncol. 2024 May 23; 8(1):114.
    View in: PubMed
    Score: 0.060
  5. Inflammatory Tongue Conditions and Risk of Oral Tongue Cancer Among the US Elderly Individuals. J Clin Oncol. 2024 May 20; 42(15):1745-1753.
    View in: PubMed
    Score: 0.058
  6. Author Correction: A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer. Nat Commun. 2022 Dec 21; 13(1):7865.
    View in: PubMed
    Score: 0.055
  7. Effect of preradiation dental intervention on incidence of osteoradionecrosis in patients with head and neck cancer: A systematic review and meta-analysis. J Am Dent Assoc. 2022 10; 153(10):931-942.e32.
    View in: PubMed
    Score: 0.053
  8. A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer. Nat Commun. 2022 08 17; 13(1):4829.
    View in: PubMed
    Score: 0.053
  9. Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. Br J Cancer. 2022 11; 127(8):1497-1506.
    View in: PubMed
    Score: 0.053
  10. Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022 Jan 03; 22(1):17.
    View in: PubMed
    Score: 0.051
  11. Application of liquid biopsy as multi-functional biomarkers in head and neck cancer. Br J Cancer. 2022 02; 126(3):361-370.
    View in: PubMed
    Score: 0.051
  12. Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. Oral Oncol. 2021 11; 122:105566.
    View in: PubMed
    Score: 0.050
  13. Ultrasensitive detection of tumor-specific mutations in saliva of patients with oral cavity squamous cell carcinoma. Cancer. 2021 05 15; 127(10):1576-1589.
    View in: PubMed
    Score: 0.048
  14. Somatic mitochondrial mutation discovery using ultra-deep sequencing of the mitochondrial genome reveals spatial tumor heterogeneity in head and neck squamous cell carcinoma. Cancer Lett. 2020 02 28; 471:49-60.
    View in: PubMed
    Score: 0.044
  15. Immune profiles in primary squamous cell carcinoma of the head and neck. Oral Oncol. 2019 09; 96:77-88.
    View in: PubMed
    Score: 0.043
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.